The anti-inflammatory potential of adenosine in ischemia-reperfusion injury: Established and putative beneficial actions of a retaliatory metabolite

Shock

Volumn 8, Issue 5, 1997, Pages 313-320

  Bouma, Maarten G ^a   Van Den Wildenberg, Frans A J M ^a   Buurman, Wim A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE KINASE; ADENOSINE RECEPTOR; ADENOSINE TRIPHOSPHATE; DRUG DERIVATIVE; ENZYME INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE; RIBONUCLEOSIDE;

ANIMAL; CARDIOVASCULAR SYSTEM; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; ISCHEMIC PRECONDITIONING; METABOLISM; REPERFUSION INJURY; REVIEW;

ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE KINASE; ADENOSINE TRIPHOSPHATE; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR SYSTEM; ENZYME INHIBITORS; HUMANS; ISCHEMIC PRECONDITIONING; NUCLEOSIDES; RECEPTORS, PURINERGIC P1; REPERFUSION INJURY; RIBONUCLEOSIDES;

EID: 0031262043     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199711000-00001     Document Type: Article

References (108)

1. Baue AE: MOF/MODS, SIRS: An update. Shock 6:S1-S5, 1996.
2. Granger DN, Rutili G, McCord JM: Superoxide radicals in feline intestinal ischemia. Gastroenterology 81:22-29, 1981.
3. McCord JM: Oxygen-derived radicals: A link between reperfusion injury and inflammation. Fed Proc 46:2402-2406, 1987.
4. Jarasch E-D, Grund C, Bruder G, Heid HW, Keenan TW, Franke WW: Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell 25:67-82, 1981.
5. Zweier JL, Kuppusamy P, Lutty GA: Measurement of endothelial cell free radical generation: Evidence for a central mechanism of free radical injury in postischemic tissues. Proc Natl Acad Sci USA 85:4046-4050, 1988.
6. Mangino MJ, Anderson CB, Murphy MK, Brunt E, Turk J: Mucosal arachidonate metabolism and intestinal ischemia-reperfusion injury. Am J Physiol 257:G299-G307, 1989.
7. Filep J, Hermán F, Braquet P, Mózes T: Increased levels of platelet-activating factor in blood following intestinal ischemia in the dog. Biochem Biophys Res Commun 158:353-359, 1989.
8. 4 in cardiac tissue and its role in infarct extension through leukocyte migration. Cardiovasc Res 22:142-148, 1988.
9. Kubes P, Ibbotson G, Russell J, Wallace JL, Granger DN: Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am J Physiol 259:G300-G305, 1990.
10. Rubin BB, Smith A, Liauw S, Isenman D, Romaschin AD, Walker PM: Complement activation and white cell sequestration in postischemic skeletal muscle. Am J Physiol 259:H525-H531, 1990.
11. Kagiyama A, Savage HE, Michael LH, Hanson G, Entman ML, Rossen RG: Molecular basis of complement activation in ischemic myocardium: Identification of specific molecules of mitochondric origin that bind human C1q and fix complement. Circ Res 64:607-615, 1989.
12. Lindsay TF, Hill J, Ortiz F, Rudolph A, Valeri CR, Hechtman HB, Moore FD Jr: Blockade of complement activation prevents local and pulmonary albumin leak after lower torso ischemia-reperfusion. Ann Surg 216:677-683, 1992.
13. Stricter RM, Coletti LM, Metinko AP, et al: The role of cytokine networks in mediating inflammation and ischemia-reperfusion injury. In Schlag G, Redl H, Traber D (eds): Shock, Sepsis and Organ Failure. Berlin: Springer Verlag, 1993, pp 205-227.
14. Kasama T, Kobatashi K, Fukushima T, et al: Production of interleukin 1-like factor from human peripheral blood monocytes and polymorphonuclear leukocytes by superoxide anion: The role of interleukin 1 and reactive oxygen species in inflamed sites. Clin Immunol Immunopathol 53:439-448, 1989.
15. Ala Y, Palluy O, Favero J, Bonne C, Modat G, Dornand J: Hypoxia/ reoxygenation stimulates endothelial cells to promote interleukin-1 and interleukin-6 production: Effects of free radical scavengers. Agents Actions 37:134-139, 1992.
16. Weiss SJ: Tissue destruction by neutrophils. N Eng J Med 320:365-376, 1989.
17. Welbourn CRB, Goldman G, Paterson IS, Valeri CR, Shepro D, Hechtman HB: Pathophysiology of ischaemia reperfusion injury: Central role of the neutrophil. Br J Surg 78:651-655, 1991.
18. Bienvenu K, Granger DN: Leukocyte adhesion in ischemia/reperfusion. Blood Cells 19:279-289, 1993.
19. Fox IH, Kelley WN: The role of adenosine and 2′deoxyadenosine in mammalian cells. Ann Rev Biochem 47:655-686, 1978.
20. Collis MG, Hourani SMO: Adenosine receptor subtypes. Trends Pharmacol Sci 14:360-366, 1993.
21. Stiles GL: Adenosine receptors. J Biol Chem 267:6451-6454, 1992.
22. Olsson RA, Pearson JD: Cardiovascular purinoreceptors. Physiol Rev 70:761-845, 1990.
23. Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 76:5-13, 1994.
24. Newby AC: Adenosine and the concept of retaliatory metabolites. Trends Biochem Sci 9:42-44, 1984.
25. Sandhu GS, Burrier AC, Janero DR: Adenosine deaminase inhibitors attenuate ischemic injury and preserve energy balance in isolated guinea pig heart. Am J Physiol 265:H1249-H1256, 1993.
26. Henrichs KJ, Matsuoka H, Schaper W: Enhanced postischemic ATP repletion by pharmacological inhibition of nucleoside washout and catabolism. J Cardiovasc Pharmacol 11:694-700, 1988.
27. Mullane K: Acadesine: The prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc Res 27:43-47, 1993.
28. Booster MH, Yin M, Maessen JG, Stubenitsky BM, Wijnen RMH, Kootstra G: Protection of canine renal grafts by renin-angiotensin inhi-bition through nucleoside transport blockade. Transplant Int 8:207-213, 1995.
29. Zughaib ME, Abd-Elfattah AS, et al: Augmentation of endogenous adenosine attenuates myocardial "stunning" independently of coronary flow or hemodynamic effects. Circulation 88:2359-2369, 1993.
30. Belardinelli L, Linden J, Berne RM: The cardiac effects of adenosine. Prog Cardiovasc Dis 32:73-97, 1989.
31. Josst HG, Steinfelder HJ: Modulation of insulin sensitivity by adenosine: Effects on glucose transport, lipid synthesis, and insulin receptors of the adipocyte. Mol Pharmacol 22:614-618, 1982.
32. 1-adenosine receptors. Am J Physiol 257:H1952-H1957, 1989.
33. 2 release during coronary occlusion and reperfusion. J Cardiovasc Pharmacol 6:442-448, 1984.
34. Schrier DJ, Imre KM: The effects of adenosine agonists on human neutrophil function. J Immunol 137:3284-3289, 1986.
35. 1 adenosine receptors in rabbit heart. Circulation 84:350-356, 1991.
36. 3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 28:1057-1061, 1994.
37. Meldrum DR, Mitchell MB, Banerjee A, Harken AH: Cardiac preconditioning. Induction of endogenous tolerance to ischemia-reperfusion injury. Arch Surg 128:1208-1211, 1993.
38. Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136, 1986.
39. Schott RJ, Rohman S, Braun ER, Schaper W: Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 66:1133-1142, 1990.
40. Deutsch E, Berger M, Kussmaul WO, Hirshfeld JW Jr, Herrmann HC, Laskey WK: Adaptation to ischemia during percutaneous transluminal coronary angioplasty: Clinical, hemodynamic, and metabolic features. Circulation 82:2044-2051, 1990.
41. Miki T, Tsuchihashi K, Miura T: Repetitive coronary occlusion by balloon inflation attenuates ischemia induced ECG-ST elevation during percutaneous transluminal coronary angioplasty. J Mol Cell Cardiol 24(Suppl. II):S13, 1992 (abstract).
42. Downey JM: Ischemic preconditioning: Nature's own cardioprotective intervention. Trends Cardiovasc Med 2:170-176, 1992.
43. Miura T, Iimura O: Infarct size limitation by preconditioning: Its phenomenological features and the key role of adenosine. Cardiovasc Res 27:36-42, 1993.
44. 3 receptors mediates preconditioning of isolated cardiac myocytes. Eur J Pharmacol 320:241-248, 1997.
45. Ishida T, Yarimizu K, Gute DC, Korthuis RJ: Mechanisms of ischemic preconditioning. Shock 1997. In press.
46. Lee HT, Schroeder CA, Shah PM, Babu SC, Thompson CI, Belloni FL: Preconditioning with ischemia or adenosine protects skeletal muscle from ischemic tissue reperfusion injury. J Surg Res 63:29-34, 1996.
47. Jerome SN, Akimitsu T, Gute DC, Korthuis RJ: Ischemic preconditioning attenuates capillary no-reflow induced by prolonged ischemia and reperfusion. Am J Physiol 268:H2063-H2067, 1995.
48. Akimitsu T, Gute DC, Korthuis RJ: Ischemic preconditioning attenuates postischemic leukocyte adhesion and emigration. Am J Physiol 271: H2052-H2059, 1996.
49. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ: Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2:1067-1069, 1972.
50. 2 receptor on human neutrophils. J Immunol 135:1366-1371, 1985.
51. 2-generation, respectively. J Clin Invest 85:1150-1157, 1990.
52. 2 receptors. J Immunol 148: 2201-2206, 1992.
53. Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R: Adenosine: A physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 158:1160-1177, 1983.
54. 2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. J Biol Chem 271: 17114-17118, 1996.
55. Grisham MB, Hernandez LA, Granger DN: Adenosine inhibits ischemia-reperfusion-induced leukocyte adherence and extravasation. Am J Physiol 257:H1334-H1339, 1989.
56. 2 receptor. Naunyn-Schmiedebergs Arch Pharmacol 346:234-237, 1992.
57. Asako H, Kubes P, Baethge BA, Wolf RE, Granger DN: Colchicine and methotrexate reduce leukocyte adherence and emigration in rat mesenteric venules. Inflammation 16:45-56, 1992.
58. Asako H, Wolf RE, Granger DN: Leukocyte adherence in rat mesenteric venules: Effects of adenosine and methotrexate. Gastroenterology 104: 31-37, 1993.
59. Firestein GS, Bullough DA, Erion MD, et al: Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor: The role of selectins. J Immunol 154:326-334, 1995.
60. Bullough DA, Magill MJ, Mullane KM, Firestein GS: Carbohydrate- and CD18-dependent neutrophil adhesion to cardiac myocytes: Effects of adenosine. Cardiovasc Res 32:328-334, 1996.
61. 2 receptors, adenosine inhibits the upregulation of Mac-1 (CD11b/CD18) expression on FMLP-stimulated neutrophils. Am J Respir Cell Mol Biol 9:179-185, 1993.
62. 3 receptors. J Immunol 158:5400-5408, 1997.
63. Inauen W, Granger DN, Meininger CJ, Schelling ME, Granger HJ, Kvietys PR: Anoxia-reoxygenation-induced, neutrophil-mediated endothelial cell injury: Role of elastase. Am J Physiol 259:H925-H931, 1990.
64. Carden DL, Korthuis RJ: Protease inhibition attenuates microvascular dysfunction in postischemic skeletal muscle. Am J Physiol 271:H1947-H1952, 1996.
65. Zimmerman BJ, Granger DN: Reperfusion-induced leukocyte infiltration: Role of elastase. Am J Physiol 259:H390-H394, 1990.
66. Binns OAR, DeLima NF, Buchanan SA, et al: Neutrophil endopeptidase inhibitor improves pulmonary function during reperfusion after eighteen-hour preservation. J Thorac Cardiovasc Surg 112:607-613, 1996.
67. Crinnion JN, Homer-Vanniasinkam S, Hatton R, Parkin SM, Gough MJ: Role of neutrophil depletion and elastase inhibition in modifying skeletal muscle reperfusion injury. Cardiovasc Surg 2:749-753, 1994.
68. Yamaguchi Y, Akizuki E, Ichiguchi O, et al: Neutrophil elastase inhibitor reduces neutrophil chemoattractant production after ischemia-reperfusion in rat liver. Gastroenterology 112:551-560, 1997.
69. Tomizawa N, Ohwada S, Ohya T, et al: Effects of neutrophil elastase inhibitor on reperfusion injury in the canine liver. Transplant Proc 28:1767-1768, 1996.
70. Welbourn CRB, Goldman G, Paterson IS, Valeri CR, Shepro D, Hechtman HB: Neutrophil elastase and oxygen radicals: Synergism in lung injury after hindlimb ischemia. Am J Physiol 260:H1852-H1856, 1991.
71. 4 synthesis in whole blood ex vivo. Br J Pharmacol 117:1639-1644, 1996.
72. 2 production. Clin Exp Immunol 57:454-460, 1984.
73. Bouma MG, Stad RK, Van den Wildenberg FAJM, Buurman WA: Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 153:4159-4168, 1994.
74. 2) receptor selective agonists. Int J Immunopharmacol 17:221-224, 1995.
75. 2 adenosine receptors. J Immunol 156:3435-3442, 1996.
76. Firestein GS, Boyle D, Bullough DA, et al: Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 152:5853-5859, 1994.
77. Parmely MJ, Zhou W-W, Edwards CK III, Borcherding DR, Silverstein R, Morrison DC: Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge. J Immunol 151:389-396, 1993.
78. 2 receptors on rat Kupffer cells. Hepatology 19:1445-1452, 1994.
79. Bouma MG, Van den Wildenberg FAJM, Buurman WA: Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol 270:C522-C529, 1996.
80. Schmidt JA, Bomford R, Gao X-M, Rhodes J: 3-Deazaadenosine: An inhibitor of interleukin 1 production by human peripheral blood monocytes. Int J Immunopharmacol 12:89-97, 1990.
81. Le Moine O, Stordeur P, Schandené L, et al: Adenosine enhances IL-10 secretion by human monocytes. J Immunol 156:4408-4414, 1996.
82. Bogdan C, Vodovotz Y, Nathan C: Macrophage deactivation by interleukin-10. J Exp Med 174:1549-1555, 1991.
83. Jurgensen CH, Huber BE, Zimmerman TP, Wolberg G: 3-Deazaadenosine inhibits leukocyte adhesion and ICAM-1 biosynthesis in tumor necrosis factor-stimulated human endothelial cells. J Immunol 144:653-661, 1990.
84. Maggirwar SB, Dhanraj DN, Somani SM, Ramkumar V: Adenosine acts as an endogenous activator of the cellular antioxidant defense system. Biochem Biophys Res Commun 201:508-515, 1994.
85. Cronstein BN, Naime D, Firestein GS: The anti-inflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum 38:1040-1045, 1995.
86. Sciotti VM, Van Wylen DG: Increases in interstitial adenosine and cerebral blood flow with inhibition of adenosine kinase and adenosine deaminase. J Cereb Blood Flow Metab 13:201-207, 1993.
87. Rosengren S, Bong GW, Firestein GS: Anti-inflammatory effects of an adenosine kinase inhibitor: Decreased neutrophil accumulation and vascular leakage. J Immunol 154:5444-5451, 1995.
88. Phillis JW, Oregan MH: Effects of an inhibitor of adenosine deaminase, deoxycoformycin, and of nucleoside transport, propentofylline, on postischemic recovery of adenine nucleotides in rat brain. Neurochem Res 21:347-353, 1996.
89. Xia Y, Khatchikian G, Zweier JL: Adenosine deaminase inhibition prevents free radical-mediated injury in the postischemic heart. J Biol Chem 271:10096-10102, 1996.
90. Van Belle H: Nucleoside transport inhibition: A therapeutic approach to cardioprotection via adenosine? Cardiovasc Res 27:68-76, 1993.
91. Mistry G, Drummond GI: Adenosine metabolism in microvessels from heart and brain. J Mol Cell Cardiol 18:13-22, 1986.
92. Galiñanes M, Qiu Y, Van Belle H, Hearse DJ: Metabolic and functional effects of the nucleoside transport inhibitor R75231 in the ischaemic and blood reperfused rabbit heart. Cardiovasc Res 27:90-95, 1993.
93. Mullane K, Bullough D, Shapiro D: From academic vision to clinical reality: A case study of acadesine. Trends Cardiovasc Med 3:227-234, 1993.
94. Bullough DA, Zhang C, Montag A, Mullane KM, Young MA: Adenosine-mediated inhibition of platelet aggregation by acadesine: A novel antithrombotic mechanism in vitro and in vivo. J Clin Invest 94:1524-1532.
95. Mathew JP, Rinder CS, Tracey JB, et al: Acadesine inhibits neutrophil CD11b upregulation in vitro and during in vivo cardiopulmonary bypass. J Thorac Cardiovasc Surg 109:448-456, 1995.
96. Akkan AG, Malaisse WJ: Insulinotropic action of AICA riboside. I. Insulin release by isolated islets and the perfused pancreas. Diabetes Res 25:13-23, 1994.
97. Gruber HE, Hoffer ME, McAllister DR, et al: Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: Effects on flow, granulocytes, and injury. Circulation 80:1400-1411, 1989.
98. Menasche P, Jamieson WRE, Flameng W, Davies MK: Acadesine: A new drug that may improve myocardial protection in coronary artery bypass grafting. Results of the first international multicenter study. J Thorac Cardiovasc Surg 110:1096-1106, 1995.
99. Lell W, Comunale M, Maddi R, et al: Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Anesthesiology 83:658-673, 1995.
100. Schoenberg MH, Poch B, Moch D, et al: Effect of acadesine treatment on post-ischemic damage to small intestine. Am J Physiol 269:H1752-H1759, 1995.
101. Spiers JP, Fabian TC, Kudsk KA, Proctor KG: Resuscitation of hemorrhagic shock with hypertonic saline/dextran or lactated Ringer's supplemented with AICA riboside. Circ Shock 40:29-36, 1993.
102. Gadangi P, Longaker M, Naime D, et al: The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J lmmunol 156:1937-1941, 1996.
103. Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate: Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92:2675-2682, 1993.
104. Harkema JM, Chaudry IH: Magnesium-adenosine triphosphate in the treatment of shock, ischemia and sepsis. Crit Care Med 20:263-275, 1992.
105. 2 in rats. J Appl Physiol 76:545-552, 1994.
106. Kerner J, Wang P, Chaudry IH: Impaired gut lipid absorptive capacity after trauma-hemorrhage and resuscitation. Am J Physiol 269:R869-R873, 1995.
107. 22 restores the depressed hepatocellular function and hepatic blood flow following hemorrhage and crystalloid resuscitation. J Surg Res 50:368-374, 1991.
108. 2 following traumahemorrhage and resuscitation: Downregulation of inflammatory cytokine (TNF, IL-6) release. J Surg Res 52:364-371, 1992.